- Hoth Therapeutics Inc (NASDAQ:HOTH) announced that HT-ALZ, a therapeutic in development for Alzheimer’s disease, achieved positive preclinical results that outpaced its previous study.
- The company said the higher dose appears to be most beneficial in a spatial memory test performed at Washington University in St Louis.
- Hoth has now completed the behavior results for Locomotor Activity/Exploratory Behavior, Elevated Plus Maze, Spatial Navigation Water Maze, Prepulse Inhibition of Startle, and Conditioned Fear and looks forward to sharing further data as it becomes available.
- “We now will begin processing the brains of the animal subjects for total plaque load and soluble/insoluble beta-amyloid levels,” said Robb Knie, CEO of Hoth Therapeutics.
- Previously Hoth reported study results focused on investigating the effect of orally administered HT-ALZ to reduce the concentration of Aβ in the brain interstitial fluid using an established Alzheimer’s Disease mouse model (aged APP/PS1+/- mice).
- The initial data from those studies showed a significant decrease in Aβ in both male and female APP/PS1+/- mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Aβ levels.
- Earlier this year, Hoth Therapeutics announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer’s disease mouse model.
- The data supports the therapeutic cognitive potential of HT-ALZ after chronic oral dosing of 20mg/kg and 40mg/kg of HT-ALZ.
- Price Action: HOTH shares are up 78.70% at $3.36 on the last check Tuesday.
Why DraftKings Stock Is Trading Higher
DraftKings Inc (NASDAQ: DKNG) shares are trading higher Friday after the company reported strong top-line results and raised its full-year guidance.
